Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America

Companies jointly developing and commercializing eplontersen in the U.S. AstraZeneca adds Latin America as part of its exclusive rights for rest of world CARLSBAD, Calif., July 28, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced it has expanded its existing…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.